Gregory A. Otterson

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer

  Investigational New Drugs · 2025-12-01 · 2 citations

• Supplementary Tables 1-5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

  2025-11-25

• Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

  2025-11-25

• Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

  2025-11-25

• Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

  2025-11-25

• Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

  2025-11-25

• Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

  2025-11-25

• Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy

  Lung Cancer · 2025-11-07

• Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

  Cancer Investigation · 2025-10-10 · 1 citations

• Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non‐Small‐Cell Lung Cancer Treated With Front‐Line Immunotherapy‐Based Therapies

  Cancer Medicine · 2025-07-28

• Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer

  Clinical Lung Cancer · 2025-07-04

• Abstract 732: Targeting adenosine A2B receptor using PBF-1129 in treating patients with metastatic non-small cell lung cancer

  Cancer Research · 2025-04-21

• Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

  OncoImmunology · 2025-02-21 · 5 citations

• 1181 Association between developing acute renal failure and one-year survival in patients with metastatic NSCLC who have received immune checkpoint inhibitor-based front-line treatment

  Regular and Young Investigator Award Abstracts · 2024-11-01

• EP.12A.04 Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer

  Journal of Thoracic Oncology · 2024-10-01

• EP.12B.10 Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)

  Journal of Thoracic Oncology · 2024-10-01 · 1 citations